About Nucleotide sugar transporter SLC35B4
Nucleotide sugar transporter SLC35B4 (SLC35B4) is a protein
from Homo sapiens identified by UniProt accession
Q969S0, 331 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Nucleotide sugar transporter SLC35B4 |
|---|
| UniProt accession | Q969S0 |
|---|
| Gene | SLC35B4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 331 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (43)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.46
- blood protein measurement · score 0.41
- platelet component distribution width · score 0.35
- insomnia measurement · score 0.28
- smoking status measurement · score 0.24
- platelet crit · score 0.19
- cutaneous melanoma · score 0.12
- hepatocellular carcinoma · score 0.07
- gonorrhea · score 0.07
- 8p23.1 microdeletion syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q969S0-F1 | alphafold | PREDICTED | 86.62 | — |
Amino-acid sequence (331 residues)
MRPALAVGLV FAGCCSNVIF LELLARKHPG CGNIVTFAQF LFIAVEGFLF EADLGRKPPA IPIRYYAIMV TMFFTVSVVN NYALNLNIAM PLHMIFRSGS LIANMILGII ILKKRYSIFK YTSIALVSVG IFICTFMSAK QVTSQSSLSE NDGFQAFVWW LLGIGALTFA LLMSARMGIF QETLYKRFGK HSKEALFYNH ALPLPGFVFL ASDIYDHAVL FNKSELYEIP VIGVTLPIMW FYLLMNIITQ YVCIRGVFIL TTECASLTVT LVVTLRKFVS LIFSILYFQN PFTLWHWLGT LFVFIGTLMY TEVWNNLGTT KSEPQKDSKK N
Explore Nucleotide sugar transporter SLC35B4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets